id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-278050-wl83d6gs	Morgenstern, Birgit	Ribavirin and interferon-β synergistically inhibit SARS-associated coronavirus replication in animal and human cell lines	2005-01-28		.txt	text/plain	2390	127	50	Abstract Initial in vitro investigations demonstrated type I interferons (IFNs: IFN-α, IFN-β) to inhibit replication of SARS coronavirus (SARS-CoV), but found the nucleoside analogue ribavirin ineffective in Vero cells. In this report, ribavirin was shown to inhibit SARS-CoV replication in five different cell types of animal or human origin at therapeutically achievable concentrations. The influence of the infectious dose on the anti-SARS-CoV activity of ribavirin was investigated in Caco2 cells infected at different MOIs by measurement of virus titre. For example, in Caco2 cells infected with SARS-CoV FFM1 strain (MOI 0.01), ribavirin concentrations inhibiting virus production in combination with IFN-b were at least 10-fold lower when compared with cultures receiving single treatment with ribavirin. These clinical findings together with the observation of antiviral activity in different SARS-CoV-infected cell lines encourage the testing of treatment strategies using ribavirin in combination with other antiviral agents such as IFNs to increase inhibitory effects on virus replication and subsequently minimised immunopathological damages.	./cache/cord-278050-wl83d6gs.txt	./txt/cord-278050-wl83d6gs.txt